The Clinical Outcomes of S-1 Plus Cisplatin for Patients with Advanced Gastric Cancer: A Meta-analysis and Systematic Review

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2018 Dec 15

PMID 30544367

Citations 2

Authors

Lei Yang

Xingcheng Wang

Binsheng Wang

Peng Chao

Debang Li

Chen Chai

Affiliations

Soon will be listed here.

Abstract

Background: To evaluate the clinical outcomes of S-1 plus cisplatin (SC) for the treatment of patients with advanced gastric cancer (AGC).

Methods: A systematic literature search was conducted by searching PubMed, the Cochrane Library, Embase, China Biology Medicine disc (CBMdisc), China National Knowledge Infrastructure (CNKI), and WanFang Database, for all year up to January 2017. Pooled analyses of overall survival (OS), progress-free survival rates, and adverse events were performed.

Results: A total of 8 random controlled trails (RCTs) consisting of 2699 patients with AGC were selected and included in this meta-analysis. The results of our meta-analysis showed that AGC patients who treated with SC regimen receive a similar OS (HR = 1.01, 95%CI: 0.86-1.18, P = .928), PFS (HR = 0.89, 95%CI: 0.72-1.09, P = .263), and overall response rate (HR = 0.88, 95%CI: 0.70-1.11, P = .283). However, SC regimen may increase the risk of 1 to 2 grade (OR = 1.128, 95%CI: 1.075-1.184, P = .000) and 3 to 4 grade (OR = 1.24, 95%CI: 1.01-1.52, P = .039) adverse events.

Conclusion: SC chemotherapy showed no difference in survival compared with 5-FU- and S-1-based other therapy, but has a higher rate of adverse events compared with other chemotherapy regimens.

Citing Articles

S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature.

Zhang C, Yu G, Zhang M, Wu W, Gong L Medicine (Baltimore). 2020; 99(3):e18892.

PMID: 32011517 PMC: 7220406. DOI: 10.1097/MD.0000000000018892.

S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature.

Zhang C, Yu G, Zhang M, Liu D Medicine (Baltimore). 2020; 99(1):e18691.

PMID: 31895837 PMC: 6946331. DOI: 10.1097/MD.0000000000018691.

References

Yang J, Zhou Y, Min K, Yao Q, Xu C . S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysis. World J Gastroenterol. 2014; 20(33):11886-93. PMC: 4155382. DOI: 10.3748/wjg.v20.i33.11886. View

Fujitani K, Yang H, Mizusawa J, Kim Y, Terashima M, Han S . Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016; 17(3):309-318. DOI: 10.1016/S1470-2045(15)00553-7. View

Koizumi W, Kim Y, Fujii M, Kim H, Imamura H, Lee K . Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2013; 140(2):319-28. PMC: 3895196. DOI: 10.1007/s00432-013-1563-5. View

Abtahi M, Koolivand A, Dobaradaran S, Yaghmaeian K, Mohseni-Bandpei A, Khaloo S . National and sub-national age-sex specific and cause-specific mortality and disability-adjusted life years (DALYs) attributable to household air pollution from solid cookfuel use (HAP) in Iran, 1990-2013. Environ Res. 2017; 156:87-96. DOI: 10.1016/j.envres.2017.03.026. View

Izuishi K, Mori H . Recent Strategies for Treating Stage IV Gastric Cancer: Roles of Palliative Gastrectomy, Chemotherapy, and Radiotherapy. J Gastrointestin Liver Dis. 2016; 25(1):87-94. DOI: 10.15403/jgld.2014.1121.251.rv2. View

Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H . Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer. 2011; 14(1):72-80. PMC: 3056989. DOI: 10.1007/s10120-011-0009-5. View

Okuyama T, Korenaga D, Edagawa A, Itoh S, Oki E, Kawanaka H . Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery. Surg Today. 2012; 42(8):734-40. DOI: 10.1007/s00595-012-0129-5. View

Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N . Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2014; 26(1):141-148. DOI: 10.1093/annonc/mdu472. View

Hess L, Michael D, Mytelka D, Beyrer J, Liepa A, Nicol S . Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data. Gastric Cancer. 2015; 19(2):607-615. PMC: 4824832. DOI: 10.1007/s10120-015-0486-z. View

10.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

11.

Li Y, Qiu M, Ming Xu J, Sun G, Lu H, Liu Y . S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015; 6(33):35107-15. PMC: 4741513. DOI: 10.18632/oncotarget.5959. View

12.

Liu Y, Feng Y, Gao Y, Hou R . Clinical benefits of combined chemotherapy with S-1, oxaliplatin, and docetaxel in advanced gastric cancer patients with palliative surgery. Onco Targets Ther. 2016; 9:1269-73. PMC: 4789894. DOI: 10.2147/OTT.S99684. View

13.

Koizumi W, Yamaguchi K, Hosaka H, Takinishi Y, Nakayama N, Hara T . Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer. Br J Cancer. 2013; 109(8):2079-86. PMC: 3798959. DOI: 10.1038/bjc.2013.555. View

14.

Koizumi W, Boku N, Yamaguchi K, Miyata Y, Sawaki A, Kato T . Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. Ann Oncol. 2009; 21(4):766-771. PMC: 2844944. DOI: 10.1093/annonc/mdp371. View

15.

Hironaka S, Sugimoto N, Yamaguchi K, Moriwaki T, Komatsu Y, Nishina T . S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2015; 17(1):99-108. DOI: 10.1016/S1470-2045(15)00410-6. View

16.

Fitzmaurice C, Allen C, Barber R, Barregard L, Bhutta Z, Brenner H . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2016; 3(4):524-548. PMC: 6103527. DOI: 10.1001/jamaoncol.2016.5688. View

17.

Lee J, Kang Y, Kang H, Lee K, Zang D, Ryoo B . A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer. 2008; 99(4):584-90. PMC: 2527839. DOI: 10.1038/sj.bjc.6604536. View

18.

Griffin-Sobel J . Gastrointestinal Cancers: Screening and Early Detection. Semin Oncol Nurs. 2017; 33(2):165-171. DOI: 10.1016/j.soncn.2017.02.004. View

19.

Ueno M, Okusaka T, Omuro Y, Isayama H, Fukutomi A, Ikeda M . A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Ann Oncol. 2015; 27(3):502-8. PMC: 4769993. DOI: 10.1093/annonc/mdv603. View

20.

Suh Y, Yang H . Screening and Early Detection of Gastric Cancer: East Versus West. Surg Clin North Am. 2015; 95(5):1053-66. DOI: 10.1016/j.suc.2015.05.012. View